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INTRODUCTION
Tumor-induced osteomalacia (TIO), also called oncogenic os-
teomalacia, is a rare paraneoplastic disorder characterized by 
renal phosphate wasting resulting in hypophosphatemia and 
impaired bone mineralization. Patients with TIO usually pres-
ent with musculoskeletal pain or muscle weakness and are 
susceptible to fractures. Typical biochemical patterns include 
hypophosphatemia, normocalcemia, normal or low levels of 
1,25-dihydroxyvitamin D [1,25(OH)2D], and elevated levels of 
alkaline phosphatase. TIO is usually caused by a small slowly 
growing tumor known as the phosphaturic mesenchymal tu-
mor mixed connective tissue variant (PMTMCT).1,2 Complete 
surgical resection is required for a cure; however, identification 
of the causative tumor is often very difficult. Imaging modali-
ties, such as magnetic resonance imaging (MRI), F-18 fluoro-
deoxyglucose positron emission tomography with computed 
tomography (FDG-PET/CT), and 111Indium-octreotide scin-
tigraphy are currently used for localization of the tumor.3 
Recently, fibroblast growth factor 23 (FGF23) was found to 
be the main pathophysiological factor for the development of 
TIO, because FGF23 reduces the expression of type 2a and 2c 
sodium-phosphate cotransporter (NPT2a and NPT2c) in the 
renal proximal tubule, thereby leading to increased phosphate 
excretion.4 Circulating FGF23 levels have been shown to be 
elevated in patients with TIO and to decrease to normal levels 
after removal of the tumor.1 Several studies have further shown 
that systemic venous sampling of FGF23 is helpful for localiza-
tion of the tumor.5-10 Therefore, our aim was to test clinical utili-
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ty of systemic venous sampling of FGF23 in patients with sus-
pected TIO in Korean patients.  
MATERIALS AND METHODS
Six patients admitted to our hospital between 2006 and 2015 
were analyzed. Symptoms and laboratory findings showing hy-
pophosphatemia and hyperphosphaturia were compatible with 
TIO. No patients had a family history of hypophosphatemic 
rickets. In cases 2 and 5 (young-age onset), a genetic test for ph-
osphate-regulating endopeptidases homolog, X-linked (PHEX), 
dentin matrix protein 1 (DMP1), and FGF23 was done for dif-
ferential diagnosis of hereditary hypophosphatemic disorders; 
these results were all negative. Laboratory data are summarized 
in Table 1. 
Functional imaging studies of 111Indium-octreotide scintig-
raphy and FDG-PET/CT were performed first, but revealed 
negative results in five patients. Subsequent whole body MRI 
revealed suspicious lesions in three patients. Thus, systemic 
venous sampling of FGF23 was conducted to detect the blind 
lesion or to confirm that a suspicious lesion on previous imag-
ing is the culprit tumor. Localized imaging at the region with 
high FGF23 levels was used next (Table 2). 
Systemic venous sampling of FGF23 was performed after 
obtaining written informed consent. By a single radiologist with 
expertise in diagnostic intervention radiology, a catheter was 
inserted through the femoral vein, and blood samples were 
collected at 10–14 sites, including the bilateral internal jugular 
veins, bilateral subclavian veins, superior vena cava, inferior 
Table 1. Baseline Clinical Characteristics of the Six Patients with Suspected Tumor-Induced Osteomalacia
Variables
Reference
range 
Patient no.
1 2 3 4 5 6
Age (yr)       50   17  48  33  20   52
Sex Male Male Male Male Male Male
Calcium (mg/dL)   8.5−10.5        8.7        8.5        8.4        9.8       9.0        9.0
Phosphate (mg/dL) 2.5−4.2        2.0        1.2        1.6        1.8        1.7        1.8
ALP (IU/L)   42−108 465 685 279 339 179 358
Creatinine (mg/dL) 0.68−1.19        0.9        0.5        0.5        0.8        0.6        0.6
PTH (pg/mL) 15−65      52.2      38.4      62.0      43.7      49.5      59.1
25(OH)D (ng/mL) 10−50      17.9        8.4      25.6      10.2        7.4        5.2
1,25(OH)2D (pg/mL) 20−60 ND      10.7        8.5      43.0      13.9        4.8
TRP* 0.85−0.95         0.75          0.45          0.88          0.71          0.44          0.81
Tmp/GFR (mg/dL)† 2.3−4.3       1.4        1.1        1.5        1.0        0.7        1.3
FGF23 (pg/mL) 10−50  375.1  1231.6    204.4      86.7    136.7    492.3
PHEX, DMP1, FGF23 gene mutation ND Negative ND ND Negative ND
ALP, alkaline phosphatase; PTH, parathyroid hormone; 25(OH)D, 25-hydroxyvitamin D; 1,25(OH)2D, 1,25-dihydroxyvitamin D; TRP, tubular reabsorption of phos-
phate; Tmp/GFR, maximal tubular reabsorption of phosphate corrected for glomerular filtration rate; FGF23, fibroblast growth factor 23; PHEX, phosphate-regu-
lating endopeptidases homolog, X-linked; DMP1, dentin matrix protein 1; ND, not done.
*TRP=[1-(serum creatinine (mg/dL)×urinary P (mg/dL)]/[serum P (mg/dL)×urinary Cr (mg/dL)], †If TRP ≤0.86, then Tmp/GFR=TRP×serum P (mg/dL), If TRP >0.86, 
then Tmp/GFR=[0.3×TRP/(1-0.8×TRP)]×serum P (mg/dL).
Table 2. A Summary of Imaging Data for the Patients 
Case
Functional images Anatomical images
Final diagnosis111Indium-octreotide
scan
FDG-PET/CT
Pre-sampling whole  
body MRI
Post-sampling
1 - ND - Rt. leg MRI + PMTMCT
2 - -  + (Pseudo) Lt. leg MRI + PMTMCT
3 - + + (Culprit) ND PMTMCT
4 - -  + (Pseudo)
H&N MRI -
PMTMCT
68Ga-DOTATOC +
5 - - - Lt. leg MRI - ND
6 - - -
H&N MRI -
PMTMCT
68Ga-DOTATOC +
FDG-PET/CT, F-18 fluorodeoxyglucose positron emission tomography with computed tomography; MRI, magnetic resonance imaging; Rt., right; Lt., left; H&N; 
head and neck; 68Ga-DOTATOC, 68Ga-DOTATOC positron emission tomography with computed tomography; PMTMCT, phosphaturic mesenchymal tumor mixed 
connective tissue variant; ND, not done. 
−, not detected; +, detected.
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vena cava, bilateral common iliac veins, bilateral femoral veins, 
and bilateral popliteal veins. FGF23 was quantified by means 
of a commercially available enzyme-linked immunosorbent 
assay kit (Kainos Laboratories, Tokyo, Japan). The diagnostic 
sensitivity was 3 pg/mL with a measurement range of 3–800 pg/
mL. The inter- and intra-assay coefficients of variation were 4% 
or less and 3% or less, respectively. 
RESULTS
Case 1
A 50-year-old man had lower-limb weakness and pain for 3 
years. He had no medical or family history of metabolic bone 
or muscular diseases. Initially, he visited the neurology de-
partment, and neurologic and laboratory examinations yield-
ed normal results, except for hypophosphatemia and elevated 
levels of alkaline phosphatase. A whole body bone scan showed 
multifocal radiotracer uptake indicative of a metabolic bone 
disease. Further evaluation revealed a reduction in maximal 
tubular reabsorption of phosphate corrected for glomerular fil-
tration rate (Tmp/GFR), suggestive of a diagnosis of TIO. How-
ever, 111Indium-octreotide scintigraphy and whole body MRI 
were not helpful for localization of the tumor, and we decided 
to perform venous sampling of FGF23. 
The patient’s serum FGF23 level in a peripheral vein was 
375.1 pg/mL (reference range: 10–50 pg/mL) and was the high-
est in the right profunda femoris vein (408.6 pg/mL, 1.2-fold 
higher than the peripheral concentration) (Fig. 1A). These find-
ings were indicative of the presence of a FGF23-producing tu-
mor adjacent to the right upper leg. MRI of the right leg revealed 
a 2.7-cm mass in the gluteus maximus muscle (Fig. 2A). The pa-
tient underwent surgical treatment, and diagnosis of PMTMCT 
was made. Serum phosphate and FGF23 levels normalized. 
Fig. 1. Results of systemic venous sampling of fibroblast growth factor 23 (FGF23) in six patients. (A) Case 1, (B) Case 2, (C) Case 3, (D) Case 4, (E) Case 
5, (F) Case 6. (a) Right (Rt.) jugular vein, (b) Left (Lt.) jugular vein, (c) Rt. subclavian vein, (d) Lt. subclavian vein, (e) superior vena cava, (f) inferior vena 
cava, (g) Rt. common iliac vein, (h) Lt. common iliac vein, (i) Rt. femoral vein, (j) Lt. femoral vein, (k) Rt. popliteal vein, (l) Lt. popliteal vein, (m) Rt. profun-
da femoris vein, (n) Lt. profunda femoris vein, (o) Rt. peroneal vein, and (p) Rt. anterior tibial vein. Numbers indicate FGF23 concentrations in pg/mL. ‘●’ 
means the finally confirmed causative tumor. 
Tumor
Tumor
Tumor
Case 1
(a) 353.5 (b) 310.7
(j) 337.8
(f) 403.4
(n) 324.3
(d) 313.7
(l) 305.4
(h) 303.1
(c) 329.8
(k) 352.5
(g) 386.4
(e) 337.9
(m) 408.6
(i) 344.8
Case 4
(a) 124.1 (b) 125.5
(j) 105.2
(f) 99.8
(l) ND
(d) 78.4
(h) 106.9
(c) 97.3
(k) ND
(g) 90.2
(e) 95.4
(i) 78.7
Case 2
(a) 1080.6 (b) 1206.7
(j) 1435.6
(f) 1097.9
(l) 1425.2
(d) 1117.0
(h) 1304.0
(c) 1172.7
(g) 1134.1
(e) 1209.5
(k) 1129.7
(i) 1104.6
Case 5
(a) 143.2 (b) 144.8
(j) 148.6
(f) 152.8
(d) 159.9
(l) 190.1
(p) 183.2
(h) 156.8
(c) 157.4
(k) 167.5
(o) 221.3
(g) 151.3
(e) 151.4
(i) 166.4
Case 3
(a) 197.7 (b) 187.3
(j) 362.9
(f) 202.3
(d) 77.9
(l) 184.7
(h) 380.4
(c) 171.5
(k) 181.7
(g) 188.5
(e) 179.8
(i) 182.4
Case 6
(a) 576.3 (b) 488.1
(j) 489.2
(f) 490.1
(d) 510.2
(l) 437.0
(h) 457.5
(c) 439.5
(k) 530.3
(g) 514.7
(e) 496.1
(i) 478.2
Tumor Tumor
A B C
D E F
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Case 2
A 17-year-old boy had pain in both knees and ankles for 4 years. 
He had a history of a femur trochanter fracture after falling and 
underwent recurrent surgical treatment due to nonunion at age 
15 and a distal humerus fracture after arm-wrestling at age 16. 
Laboratory data showed low levels of serum phosphate and up-
regulated alkaline phosphatase. Bone mineral density (BMD) 
measured by dual-energy X-ray absorptiometry revealed se-
verely low bone mass in the lumbar spine (Z-score -3.7) and to-
tal hip (Z-score -5.0). Mutations of PHEX, DMP1, and FGF23 
were absent, suggestive of TIO. 111Indium-octreotide scintigra-
phy and FDG-PET/CT did not show a suspected tumor, and 
whole body MRI identified a 1-cm focal lesion in the right mi-
dtibia, raising suspicions of a hemangioma or osteomalacic le-
sion. He underwent a surgical intervention, but histopathologi-
cal examination revealed woven bone formation. There was also 
no improvement in symptoms. Therefore, we performed sys-
temic venous sampling of FGF23. 
The serum FGF23 level in a peripheral vein was 1231.6 pg/mL 
and was the highest in the left femoral vein (1435.6 pg/mL), 
1.3-fold higher than the peripheral concentration (Fig. 1B). MRI 
of the left leg was done, and we found a 4.2-cm mass in the pos-
terior aspect of the ankle abutting the peroneal artery and vein 
(Fig. 2B). By a two-stage operation, the tumor was completely 
resected, and histopathological analysis revealed PMTMCT. 
Serum phosphate and FGF23 rapidly normalized. The lumbar 
spine and total hip BMD increased by 40% (lumbar spine Z 
score -1.2, total hip Z score -1.7) after 5 months and finally nor-
malized after 17 months.
Case 3
A 48-year-old man was referred to us with complaints of hip 
pain and decreased height (by 5 cm) for 1 year. Biochemical 
analysis showed hypophosphatemia, decreased Tmp/GFR, and 
24-hour urinary glucose at 15057 mg (reference range: 500–
1500 mg/day) without diabetes. We suspected both acquired 
Fanconi syndrome and TIO. However, characteristics of typical 
Fanconi syndrome, including metabolic acidosis, proteinuria, 
or hypouricemia, were all negative. 111Indium-octreotide scintig-
raphy yielded negative results. However, FDG-PET/CT and MRI 
identified a 0.8-cm round lesion in the left femoral head (Fig. 2C 
and D). Thus, systemic venous sampling of FGF23 was con-
ducted. 
The serum FGF23 level in a peripheral vein was 204.4 pg/mL 
and was the highest in the left common iliac vein (380.4 pg/mL, 
1.9-fold higher than the peripheral concentration) (Fig. 1C). 
These results strongly suggested that the tumor in his left fem-
oral head was responsible for the TIO. After left total hip re-
placement for removal of the tumor, serum FGF23 decreased to 
an undetectable level, and symptoms improved significantly. 
The pathologic diagnosis was PMTMCT. 
Case 4
A 33-year old man was admitted with aggravating back pain. 
He began to experience the pain and stiffness at the age of 20 
years, and symptoms continued to worsen. Laboratory exami-
Fig. 2. Imaging data from patients with tumor-induced osteomalacia (TIO). (A) Magnetic resonance imaging (MRI) of the right thigh in case 1 shows a 2.7-
cm oval mass within the right gluteus maximus. (B) MRI of the left foot in case 2 reveals a 4.2-cm lobulated mass in the posterior aspect of the ankle. 
(C) MRI of the left hip in case 3 shows a 0.8-cm, well-defined, round lesion in the left femoral head. (D) F-18 fluorodeoxyglucose positron emission to-
mography with computed tomography (FDG-PET/CT) in case 3 reveals mild FDG uptake in the left femoral head. (E) 68Ga-DOTATOC PET/CT in case 4 
shows increased uptake in the right mandible. (F) MRI of the neck in case 4 with focal enhancement in the right mandible. (G) 68Ga-DOTATOC PET/CT 
in case 6 shows increased FDG uptake in the left ethmoid and nasal cavity. (H) Computed tomography of the paranasal sinus in case 6 reveals a 1.8-
cm soft-tissue lesion in the left ethmoid sinus. Arrows indicate the tumors responsible for TIO.
A
E
B
F
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D
H
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nation showed hypophosphatemia and decreased Tmp/GFR. 
Imaging by 111Indium-octreotide scintigraphy and FDG-PET/
CT yielded negative results, while whole body MRI revealed a 
small mass in his right tibia with decreased trabeculation. He 
underwent surgical intervention, and histopathological ex-
amination revealed an intraosseous lipoma. Postoperatively, he 
was treated with calcium, vitamin D, and oral phosphate. At 
5-year follow-up, he complained of lower-leg pain again, and 
follow-up MRI revealed a newly developed 2.8-cm enhancing 
mass in the right proximal tibia, suggestive of an intraosseous 
lipoma. To verify that the mass was responsible for TIO, we per-
formed systemic venous sampling of FGF23. 
The serum FGF23 level in a peripheral vein was 86.7 pg/mL 
and lower than average in the right femoral vein (78.7 pg/mL) 
(Fig. 1D). These results suggested that the mass found on MRI 
was a lipoma, rather than an FGF23-producing tumor. Because 
the FGF23 concentration in both jugular veins were respectively 
125.5 and 124.1 pg/mL, 1.3-fold higher than average (the high-
est), secondary venous sampling was focused on head and neck 
veins, including the bilateral subclavian vein, internal jugular 
vein, sigmoid sinus vein, transverse sinus vein, and superior and 
inferior sagittal sinus veins. FGF23 levels were highest in the 
right internal jugular vein (144.3 pg/mL), although the differ-
ence in comparison to the other veins was minimal. MRI of the 
head and neck did not identify a suspicious lesion either. Ac-
cordingly, he received medical supplementation with calcium, 
active vitamin D, and oral phosphate.
At 3-year follow up, we conducted 68Ga-DOTATOC PET/CT. 
We noted increased gallium uptake in the right mandible (Fig. 
2E). Subsequent neck MRI demonstrated focal enhancement 
in the right mandible and adjacent buccal mucosa (Fig. 2F). 
As he had a history of tooth extraction (#46, 47) of that area with 
chronic periodontitis, an excisional surgery was performed. 
Histopathologic examination revealed giant cell granuloma 
with unmineralized osteoid formation, an entity that may be 
included in the PMTMCT.11 His serum phosphate and FGF23 
levels normalized after the removal without medication. We 
planned to carefully follow up laboratory and clinical signs. 
Case 5
A 20-year-old man was referred to us with pain in both wrists 
lasting for 10 years. A laboratory investigation revealed hypo-
phosphatemia and markedly decreased Tmp/GFR. Because of 
suspected hypophosphatemic rickets, a genetic test was per-
formed, although the results were all negative. Various imag-
ing modalities, including 111Indium-octreotide scintigraphy, 
FDG-PET/CT and whole body MRI, were conducted to detect 
the causative lesion; however, all yielded negative results. We 
decided to perform systemic venous sampling of FGF23. 
The serum FGF23 level in a peripheral vein was 136.7 pg/mL, 
with a peak in his left peroneal vein (221.3 pg/mL, 1.4-fold 
higher than the peripheral level) (Fig. 1E). However, subse-
quent localized MRI failed to detect the responsible tumor. He 
is still on medical replacement of calcium, active vitamin D, 
and oral phosphate.
Case 6
A 52-year-old man presented with generalized bone pain last-
ing for 6 months. He had a history of surgical treatment of a ver-
tebral fracture at age 50 years, and his laboratory findings were 
compatible with TIO. 111Indium-octreotide scintigraphy, FDG-
PET/CT, and whole body MRI were performed, but with neg-
ative results. Thus, we conducted systemic venous sampling 
of FGF23. 
The serum FGF23 level in a peripheral vein was 492.3 pg/
mL and was highest in the right jugular vein (576.3 pg/mL), 
1.2-fold higher than the peripheral level (Fig. 1F). However, 
MRI of the head and neck did not reveal a suspicious tumor. 
Accordingly, he was treated with medical replacement of cal-
cium, active vitamin D, and oral phosphate. 
At 3-year follow-up, we performed 68Ga-DOTATOC PET/CT. 
There was increased gallium uptake in the left ethmoid and 
nasal cavity (Fig. 2G). Subsequent CT confirmed a 1.8-cm, soft-
tissue lesion in the left ethmoid sinus (Fig. 2H). He underwent 
surgical treatment, and PMTMCT was diagnosed. Because 
the resection was incomplete, postoperative radiation therapy 
was administered. After completion of the radiation therapy, 
serum phosphate levels normalized, and MRI showed no re-
sidual visible tumor.  
In summary, five patients out of six achieved a complete cure 
after surgical resection, and only one patient is still on medi-
cal supplementation. Diagnostic modalities helpful for detec-
tion of the tumor were venous sampling of FGF23 (83%, 5/6), 
followed by post-sampling localized MRI (cases 1, 2, and 3) 
and 68Ga-DOTATOC PET/CT (case 4, 6). In case 5, an approxi-
mate location was suggested by venous sampling of FGF23; 
however, MRI of the suspicious site could not identify the le-
sion. Both 111Indium-octreotide scintigraphy (0%, 0/6) and 
FDG-PET/CT (20%, 1/5) were not helpful in our cases. 
DISCUSSION
TIO was first reported in 1947 by McCance12 who described a 
15-year-old girl with symptoms of TIO and resistance to vita-
min D treatment. While her symptoms were resolved after tu-
mor resection, the relationship between the tumor and bone 
disease was not clearly recognized.12 In 1959, Prader, et al.13 rec-
ognized that a “rachitogenic” substance secreted by the tumor 
was the cause of TIO. The tumor responsible for TIO is small 
and grows slowly, and is usually located in bone, a soft tissue, 
or the head or neck. Thus, this lesion is difficult to identify by 
conventional imaging methods.14 This situation delays diag-
nosis often by several years: it takes up to 2.5 years to recog-
nize TIO after patients experience symptoms and usually 
more than 5 years to localize the causative tumor.15,16 
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111Indium or 99mTechnetium octreotide scintigraphy has 
been used for the detection of TIO, because a mesenchymal 
tumor causing TIO often expresses somatostatin receptors 
(SSTRs), which enable visualization of the tumor by octreotide 
scintigraphy.17 In studies by Jiang, et al.18 46 of 94 patients (48%), 
in whom the tumor was not localized successfully by other im-
aging modalities, showed a tumor on octreotide scintigraphy. 
Forty of them underwent surgical treatment, and in 37 patients, 
the diagnosis was histologically confirmed.
FDG-PET/CT has shown good sensitivity in various re-
ports.19-21 In the largest survey, which was conducted by Jagtap, 
et al.20 FDG-PET/CT localized tumors in seven of eight patients 
(87%). TIO was pathologically confirmed in four patients, was 
false positive in one patient, and histopathological confirma-
tion was not performed in two patients. In a recent trial by 
Agrawal, et al.21 FDG-PET/CT detected a tumor in two out of 
four patients (50%), and TIO was confirmed by histopathology. 
Meanwhile, in the present study, only one of five patients (20%, 
case 3) showed increased FDG uptake in FDG-PET/CT, far 
below what was expected. This could be explained as follows: 
the tumor grows very slowly and, thus, is less hypermetabolic 
or vascular than can be detected by FDG-PET/CT.
FGF23 is a well-known phosphaturic factor, “phosphatonin,” 
secreted by the tumors causing TIO.22 Other known potential 
phosphatonins include secreted frizzled related protein 4 and 
matrix extracellular phosphoglycoprotein. They play a major 
role in the pathophysiology of TIO, autosomal dominant hy-
pophosphatemic rickets, and X-linked hypophosphatemia.23 
FGF23 is a polypeptide hormone belonging to the FGF19 su-
perfamily. It is produced by bone and exerts effects in the kid-
neys. By binding to target cells forming the Klotho-FGF recep-
tor complex, it transduces signals to inhibit NPT2a and NPT2c 
transporters in the proximal renal tubule, thereby activating re-
nal phosphate excretion. FGF23 also plays a role in 1,25(OH)2D 
metabolism by inhibiting 1α-hydroxylase, leading to a de-
crease in 1,25(OH)2D levels.1,3 FGF23 concentration is elevat-
ed in patients with TIO and normalizes after surgical resection 
of the tumor.24 
Venous sampling of FGF23 was first used for the diagnosis 
of TIO in 2004,6 and additional case reports followed.5,7-10 Of a 
total of 28 patients, researchers were able to localize tumors in 
19 patients (67%) by FGF23 sampling, and the patients achieved 
a complete cure after surgical treatment. In the present study, 
FGF23 sampling was useful in five of six patients (83%). They 
(cases 1, 2, 3, 4, and 6) had an especially high FGF23 level in a 
certain vein, and the relevant anatomical lesion was found by 
subsequent additional imaging studies. In contrast, one pa-
tient (cases 5) had elevated FGF23 levels in a focal area but no 
plausible lesion on subsequent imaging. This result suggests 
that venous sampling of FGF23 is helpful for estimating the 
location of the tumor, as well as confirming the diagnosis in 
the presence of the related lesion on other imaging modalities. 
At present, SSTR imaging can be performed with better res-
olution by means of 68Ga-DOTATOC, 68Ga-DOTANOC, or 68Ga-
DOTATATE PET/CT. This approach combines the specificity 
of octreotide scintigraphy and sensitivity of PET/CT, thus 
emerging as a new diagnostic tool.21,25 In one study comparing 
111Indium-octreotide scintigraphy and 68Ga-DOTATATE PET/
CT in five patients, octreotide scintigraphy detected tumors in 
only one patient, while 68Ga-DOTATATE PET/CT identified 
tumors in all five patients.26 This finding can be explained by a 
higher affinity for SSTR2 in 68Ga-DOTA conjugated PET/CT, 
which allows for visualization of a previously undetectable tu-
mor.27 In our study, octreotide scintigraphy was not helpful for 
diagnosis in all six patients, while 68Ga-DOTATOC PET/CT 
helped to detect the tumor in cases 4 and 6. 
Nevertheless, this does not mean that FGF23 sampling has 
low clinical value. In cases 2 and 4, patients underwent surgical 
treatment according to the assumption that the mass detected 
by MRI was responsible for TIO. However, we later found that 
this mass was misidentified. There is a chance that MRI will 
detect a lesion false positively; moreover, it is impossible to 
determine whether a mass is responsible for TIO by means of 
imaging only. In such circumstances, venous sampling of 
FGF23 may be helpful by demonstrating the location of the 
FGF23-producing tumor. In case 4, the patient was able to avoid 
an unnecessary surgical procedure, because the location of 
elevated FGF23 was not relevant to the mass visible on MRI.
In terms of threshold values, the highest level of FGF23 was 
1.2- to 1.5-fold higher than the peripheral level, lower than that 
in other case reports in which a 1.5- to 3.0-fold elevation was 
recorded.5,10 Only a 20% increase can be useful for detecting tu-
mors when there is an overall rise in FGF23 levels.
This study has some limitations: we did not perform muta-
tion testing in all patients; therefore, genetic causes of hypo-
phosphatemia could not completely ruled out. In addition, we 
analyzed only a small patient population (in whom we con-
ducted systemic venous sampling of FGF23), because TIO is a 
very rare disease. Despite these limitations, we showed the val-
ue of venous sampling of FGF23 for predicting the location of 
the tumor in Korean patients for the first time. This approach 
can be more powerful in the presence of a related lesion on 
subsequent imaging studies. 
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